[Hypertension and arteriosclerosis]. 1992

A C Pessina, and P Pauletto, and G P Rossi, and R Valle
Cattedra di Medicina Interna, Università degli Studi di Padova.

Arterial hypertension is a major risk factor for atherosclerosis. The mechanisms involved include elevation of blood pressure, increased velocity of the sphygmic wave and increased blood flow turbulence. These hemodynamic features however do not fully explain the link between hypertension and atherosclerosis. An important role is also played by humoral factors including catecholamines, the renin-angiotensin-aldosterone system, serotonin, endothelin, platelets and endothelium-derived growth factors. Furthermore in the last few years great relevance has been attributed to hyperinsulinemia (accompanied by hypercholesterolemia and hypertriglyceridemia) that is frequently found in hypertensive subjects. Several recent reports on the antiatherogenic effect of some antihypertensive agents that could slow down the progression of atherosclerotic lesions in hypertensive subjects are promising.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D001161 Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. Arterioscleroses
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D050356 Lipid Metabolism Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS. Metabolism, Lipid
D018377 Neurotransmitter Agents Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. Nerve Transmitter Substance,Neurohormone,Neurohumor,Neurotransmitter Agent,Nerve Transmitter Substances,Neurohormones,Neurohumors,Neuromodulator,Neuromodulators,Neuroregulator,Neuroregulators,Neurotransmitter,Neurotransmitters,Substances, Nerve Transmitter,Transmitter Substances, Nerve,Substance, Nerve Transmitter,Transmitter Substance, Nerve

Related Publications

A C Pessina, and P Pauletto, and G P Rossi, and R Valle
April 1953, Vie medicale (Paris, France : 1920),
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
January 2011, Nihon rinsho. Japanese journal of clinical medicine,
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
January 1975, Kardiologia polska,
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
August 1960, American heart journal,
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
April 1956, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
July 1967, Das Deutsche Gesundheitswesen,
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
May 1935, British medical journal,
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
April 1966, Lebensversicherungs Medizin,
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
September 1959, Deutsche medizinische Wochenschrift (1946),
A C Pessina, and P Pauletto, and G P Rossi, and R Valle
June 1961, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!